Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 51

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 51
---
 with our limited resources.

    ●
    We depend upon our senior management and key consultants and their loss or unavailability could put us at a competitive disadvantage.

    ●
    The biotechnology and immunotherapy industries are characterized by rapid technological developments and a high degree of competition. We may be unable to compete with more substantial enterprises.

    ●
    We can provide no assurance that our clinical product candidates will obtain regulatory approval or that the results of clinical studies will be favorable.

    ●
    Drug discovery and development is a complex, time-consuming and expensive process with a high rate of failure.

    ●
    We may face legal claims; legal disputes are expensive, and we may not be able to afford the costs.

    ●
    We can provide no assurance of the successful and timely development of new products.

    ●
    We must comply with significant government regulations.

29

    ●
    We rely upon patents to protect our technology. We may be unable to protect our intellectual property rights.

    ●
    The price of our common stock may be volatile.

    ●
    The market prices for our common stock may be adversely impacted by future events.

    ●
    A limited public trading market may cause volatility in the price of our common stock.

    ●
    Our Rights Agreement contains anti-takeover provisions that could discourage, delay or prevent a change in control, which may cause our stock price to decline.

You should carefully consider
the risks described below as well as other information provided to you in this document, including information in the section of this
document entitled “Information Regarding Forward Looking Statements.” If any of the following risks actually occur, the Company’s
business, financial condition or results of operations could be materially adversely affected, the value of the Company’s Common
Stock could decline, and you may lose all or part of your investment.

RISKS RELATED TO OUR BUSINESS

There is doubt about our ability to continue
as a going concern.

As of December 31, 2024, the
Company had an accumulated deficit of $163,104,000. Losses have principally occurred as a result of the substantial resources required
for research and development of the Company’s product candidates which included the general and administrative expenses associated
with its organization and product development as well as the lack of sources of revenues until such time as the Company’s products
are commercialized. These factors raise substantial doubt about the Company’s ability to continue as a going concern for the 12
months from the issuance date